Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Martin Watterson

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Experimental Cell Research|July 22, 2004
Myosin light chain kinase (210 kDa) is a potential cytoskeleton integrator through its unique N-terminal domainDmitry S Kudryashov, Olga V Stepanova, Elena L Vilitkevich, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 26, 2014
An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosisShannon L Macauley, Andrew M S Wong, Charles Shyng, et al.
Plos One|February 13, 2016
MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological ResponsesAdam D Bachstetter, Zhengqiu Zhou, Rachel K Rowe, et al.
Plos One|December 15, 2010
Homodimerization of the death-associated protein kinase catalytic domain: development of a new small molecule fluorescent reporterMichael Zimmermann, Cédric Atmanene, Qingyan Xu, et al.
Clinical Pharmacology in Drug Development|April 8, 2020
First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult VolunteersLinda J Van Eldik, Lumy Sawaki, Karen Bowen, et al.
American Journal of Respiratory Cell and Molecular Biology|February 9, 2010
Non-muscle myosin light chain kinase isoform is a viable molecular target in acute inflammatory lung injuryTamara Mirzapoiazova, Jaideep Moitra, Liliana Moreno-Vinasco, et al.
ACS Chemical Neuroscience|February 14, 2015
Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse modelsSaktimayee M Roy, Valerie L Grum-Tokars, James P Schavocky, et al.
The Journal of Clinical Investigation|November 18, 2025
USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-IKun Liu, Radhika Iyer, Yi Li, et al.
Plos One|July 11, 2013
Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic DysfunctionD Martin Watterson, Valerie L Grum-Tokars, Saktimayee M Roy, et al.
Plos One|June 19, 2013
Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinaseGerardo A Morfini, Daryl A Bosco, Hannah Brown, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Experimental Cell Research|July 22, 2004
Myosin light chain kinase (210 kDa) is a potential cytoskeleton integrator through its unique N-terminal domainDmitry S Kudryashov, Olga V Stepanova, Elena L Vilitkevich, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 26, 2014
An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosisShannon L Macauley, Andrew M S Wong, Charles Shyng, et al.
Plos One|February 13, 2016
MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological ResponsesAdam D Bachstetter, Zhengqiu Zhou, Rachel K Rowe, et al.
Plos One|December 15, 2010
Homodimerization of the death-associated protein kinase catalytic domain: development of a new small molecule fluorescent reporterMichael Zimmermann, Cédric Atmanene, Qingyan Xu, et al.
Clinical Pharmacology in Drug Development|April 8, 2020
First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult VolunteersLinda J Van Eldik, Lumy Sawaki, Karen Bowen, et al.
American Journal of Respiratory Cell and Molecular Biology|February 9, 2010
Non-muscle myosin light chain kinase isoform is a viable molecular target in acute inflammatory lung injuryTamara Mirzapoiazova, Jaideep Moitra, Liliana Moreno-Vinasco, et al.
ACS Chemical Neuroscience|February 14, 2015
Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse modelsSaktimayee M Roy, Valerie L Grum-Tokars, James P Schavocky, et al.
The Journal of Clinical Investigation|November 18, 2025
USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-IKun Liu, Radhika Iyer, Yi Li, et al.
Plos One|July 11, 2013
Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic DysfunctionD Martin Watterson, Valerie L Grum-Tokars, Saktimayee M Roy, et al.
Plos One|June 19, 2013
Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinaseGerardo A Morfini, Daryl A Bosco, Hannah Brown, et al.
Pageof 8